SenzaGen signs agreement with international pharmaceutical company
26 January 2016
Skåne-based company, SenzaGen, a developer of technology for animal free testing of chemicals , signs a strategic contract with an international pharma company, marking its entry into the pharmaceutical industry.
This is the first time that a pharmaceutical customer will use SenzaGen's method, GARD, which has, so far, only been used within the cosmetic industry. The main advantage of using GARD is that the test is based on genomic technology and is performed in vitro. The tests can be performed in a very early phase of drug development, which will help pharmaceutical companies develop safer drugs, at a faster pace, and at a lower cost.
"Since the start, collaborations with pharmaceutical companies have been a major objective for SenzaGen. We see great potential in this market and we are looking forward to learning more about the industry, with an ambition to develop and offer GARD to even more customers in the pharmaceutical industry", says Anki Malmborg Hager, CEO SenzaGen Read the full press release on SenzaGen's website